CIS-DIAMMINEDICHLOROPLATINUM II

Adenocarcinoma

Mayo ClinicSmall moleculePhase 4 / ApprovedActive

BBB

76/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 67/ 100
Competitive Position: 89/ 100

Competitive context

26 Active assets in the Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
Carboplatin Blueprint Medicines Corporation	Phase 4	BBB
Irinotecan University of Chicago	Phase 2	BBB
Cyclophosphamide M.D. Anderson Cancer Center	Phase 3	BB
Icotinib Betta Pharmaceuticals Co., Ltd.	Phase 4	BB
Desflurane University of Zurich	Phase 4	BB

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant

BBB

Indicative ·

78 / 100

primary peritoneal carcinomaDormant

BBB

Indicative ·

77 / 100

Nasal and Nasal-type NK/T-cell LymphomaDormant

BBB

Indicative ·

75 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.